Celldex Therapeutics, Inc. (CLDX) – What Are Investment Firms Thinking About This Stock?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $64.08.

Several analysts recently weighed in on the company. Wells Fargo & Company lifted their price target on Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Barclays increased their price objective on Celldex Therapeutics from $48.00 to $53.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. HC Wainwright reissued a “buy” rating and set a $64.00 target price on shares of Celldex Therapeutics in a report on Friday, October 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Thursday, October 15th. Finally, Cantor Fitzgerald boosted their target price on shares of Celldex Therapeutics from $61.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 22nd.

Celldex Therapeutics News Roundup

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates for Q4 2026, FY2026 and FY2027, forecasting losses of $0.99, $4.05 and $4.28 per share, respectively, versus prior estimates of $1.08, $4.23 and $4.49 in losses. The firm maintained its Buy rating and $64 price target.
• Positive Sentiment: Canaccord Genuity raised its price target to $68 from $60 and reiterated a Buy rating. Canaccord Genuity rating update
• Positive Sentiment: Morgan Stanley lifted its target to $61 from $57 and maintained an Overweight rating. Morgan Stanley rating update
• Neutral Sentiment: A head-to-head survey comparing Celldex with Oncobiologics (OTLK) was listed, but the supplied item contains no findings or company-specific news to assess. Head-to-head survey article

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $31.24 on Tuesday. Celldex Therapeutics has a 52 week low of $22.10 and a 52 week high of $45.14. The firm has a market cap of $2.45 billion, a P/E ratio of -7.27 and a beta of 1.04. The firm’s 50-day simple moving average is $32.77 and its 200 day simple moving average is $32.70.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.06. The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.72 million. As a group, equities analysts forecast that Celldex Therapeutics will post -4.17 earnings per share for the current year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds have recently bought and sold shares of CLDX. Diversified Trust Co boosted its holdings in Celldex Therapeutics by 2.9% in the 3rd quarter. Diversified Trust Co now owns 32,239 shares of the biopharmaceutical company’s stock valued at $1,045,000 after purchasing an additional 909 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Celldex Therapeutics by 26.5% during the third quarter. Fisher Asset Management LLC now owns 1,246,855 shares of the biopharmaceutical company’s stock worth $40,411,000 after purchasing an additional 261,178 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Celldex Therapeutics by 11.0% during the third quarter. Russell Investments Group Ltd. now owns 111,489 shares of the biopharmaceutical company’s stock worth $3,613,000 after purchasing an additional 11,037 shares during the period. Three Bridge Wealth Advisors LLC bought a new position in shares of Celldex Therapeutics during the third quarter worth approximately $40,000. Finally, Candriam S.C.A. raised its position in shares of Celldex Therapeutics by 7.8% in the third quarter. Candriam S.C.A. now owns 518,476 shares of the biopharmaceutical company’s stock valued at $16,865,000 after buying an additional 37,351 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company that develops antibody-based treatments for inflammatory diseases and cancer. Its research focuses on targets involved in immune responses and the activity of mast cells.

The company’s lead candidate, barzolvolimab, is an antibody that targets the KIT receptor. Celldex is studying it for chronic urticaria and other conditions associated with mast-cell activity.

Celldex also has early-stage oncology programs that investigate antibody therapies designed to affect immune pathways.